Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · Real-Time Price · USD
20.09
-1.08 (-5.10%)
Mar 13, 2025, 1:19 PM EDT - Market open
Celldex Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Celldex Therapeutics stock have an average target of 55.67, with a low estimate of 36 and a high estimate of 80. The average target predicts an increase of 177.10% from the current stock price of 20.09.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Celldex Therapeutics stock from 7 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
---|---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
Buy | 2 | 2 | 1 | 1 | 1 | 1 |
Hold | 3 | 3 | 3 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 8 | 8 | 7 | 7 | 7 | 7 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Goldman Sachs | Goldman Sachs | Hold Maintains $42 → $36 | Hold | Maintains | $42 → $36 | +79.19% | Mar 3, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +298.21% | Mar 3, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +298.21% | Feb 28, 2025 |
UBS | UBS | Strong Buy Initiates $44 | Strong Buy | Initiates | $44 | +119.01% | Feb 13, 2025 |
Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $67 | Buy | Reiterates | $67 | +233.50% | Jan 29, 2025 |
Financial Forecast
Revenue This Year
3.48M
from 7.02M
Decreased by -50.47%
Revenue Next Year
4.42M
from 3.48M
Increased by 27.01%
EPS This Year
-3.32
from -2.45
EPS Next Year
-3.82
from -3.32
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 12.6M | 12.6M | 93.3M | ||
Avg | 3.5M | 4.4M | 37.2M | ||
Low | n/a | n/a | n/a |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 79.5% | 262.4% | 2,013.8% | ||
Avg | -50.5% | 27.0% | 741.5% | ||
Low | - | - | - |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -2.58 | -2.32 | -4.14 | ||
Avg | -3.32 | -3.82 | -4.11 | ||
Low | -3.59 | -4.70 | -4.04 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.